SCHEMBL24843299

SCHEMBL24843299

CC(C)CNCCc1cccc(-c2cccc(CNCC(C)C)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.47
HTR1A P08908 2/20 0.44
PRMT6 Q96LA8 2/20 0.43
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 2/20 0.42
ADRB2 P07550 1/20 0.42
CYP2C19 P33261 1/20 0.42
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
PGGT1B P53609 1/20 0.41
KDM4E B2RXH2 1/20 0.41
BCHE P06276 2/20 0.41
CA2 P00918 3/20 0.41
NMT1 P30419 1/20 0.41
SLC2A1 P11166 1/20 0.40
HDAC1 Q13547 2/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15859356 0.81 CA2 (0.49) MAP4K4ALDH1A1CYP1A2ADRB2BCHE
SCHEMBL29778343 0.81 CHRM2 (0.49) MAP4K4HTR1APRMT6CYP1A2CYP2C19
SCHEMBL16264585 0.81 CHRM2 (0.45) MAP4K4HTR1APRMT6CYP1A2CYP2C19
SCHEMBL16264621 0.81 CHRM2 (0.49) MAP4K4HTR1APRMT6CYP1A2CYP2C19
Hydrochloric Acid SCHEMBL29778279 0.80 CHRM2 (0.44) MAP4K4HTR1APRMT6CYP1A2CYP2C19
SCHEMBL1566434 0.78 TAAR1 (0.62) ALDH1A1CYP1A2CYP2C19SLC2A1HDAC1
SCHEMBL552305 0.78 TAAR1 (0.62) ALDH1A1CYP1A2CYP2C19KDM4ECYP2D6
SCHEMBL21648402 0.77 SCN8A (0.49) MAP4K4HTR1ACYP1A2CYP2C19CYP2D6
SCHEMBL13416723 0.76 ALDH1A1 (0.56) ALDH1A1CYP1A2ADRB2CYP2C19GAA
Hydrochloric Acid SCHEMBL29885630 0.76 SCN8A (0.48) MAP4K4HTR1ACYP1A2CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2023-08-15 US disclosed
US-20230002378-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS STORM THERAPEUTICS LIMITED (GB) 2023-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002378-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, DIMT1, TPMT MAP4K4 3645/4885HTR1A 2943/4885PRMT6 69/4885
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors METTL3, DIMT1, TPMT MAP4K4 3645/4885HTR1A 2943/4885PRMT6 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.